About EEP
Investment Orientation
The Team






Investor Reporting
Contact Us
Site Map
Terms & Conditions

David Kauffmann

David is founding managing partner of EEP, the chairman of CMC Biologics and ARTS Biologics and also serves on the Board of Azanta. Until the merger with SGS in January 2006, he also held the position of Chairman of the Management Board of Aster Cephac.

Prior to EEP, from 1990, David was a partner of CAI, a North American US$150 million private equity investment fund with offices in New York, Montreal, London and Paris, investing in US$30 million plus situations. In 1992 he started CAI's European investment activities. At CAI David was actively involved in investing in Aster Cephac and Bioresearch.  

David has invested in early-stage, development and replacement capital within the healthcare, telecommunications and light manufacturing industries. David is particularly interested in and has worked with a number of R&D service companies in the pharmaceutical industry.

Prior to working in private equity and venture capital, David worked for the American Express Bank in London, New York and Copenhagen, in acquisitions and trade finance. He holds an MBA from IMD in Lausanne, Switzerland, and a BSc from the Copenhagen School of Economics and Business Administration.


EEP Advisers Limited is Authorised and Regulated by the Financial Conduct Authority